The negotiated "maximum fair price" for drugs under the Inflation Reduction Act will represent a discount of 25% to 60% off their 2021 price, depending on the age of the drug.

Mitali Desai predicts that hospitals will regain full access to 340B pricing at contract pharmacies by 2026.

Medicare is scheduled to release the final list of the first 10 drugs selected for price negotiation under the Inflation Reduction Act on September 1st.

The Inflation Reduction Act's Medicare drug price negotiation program will begin with 10 Part D drugs in 2026, add 15 more Part D drugs in 2027, add 15 Part B drugs in 2028, and add 20 new drugs annua...

UMass Memorial Medical Center's analysis projects an annualized negative financial impact of $3.5 million from the Inflation Reduction Act's drug pricing provisions, based on the initial 10 drugs.

UMass Memorial Medical Center provided approximately $229 million in uncompensated care and $20 million in community benefits during fiscal year 2022.

The Inflation Reduction Act will eliminate the 340B savings spread for Medicare patients on negotiated drugs because Medicare reimbursement will be lowered to the new "maximum fair price".

The "maximum fair price" established by the Inflation Reduction Act will become the new "best price" in the 340B pricing formula, which will lower the 340B ceiling price for those drugs.

Astellas, the manufacturer of Xtandi, has recently announced it will implement 340B pricing restrictions for contract pharmacies.

Lowering the 340B ceiling price due to the Inflation Reduction Act will increase 340B savings for hospitals on drugs dispensed to commercially insured patients.

In recent months, several drug manufacturers have eliminated the option for hospitals to maintain 340B pricing at contract pharmacies by sharing claims data via the 340B ESP portal.

In UMass Memorial Medical Center's financial impact analysis of the IRA, the drug Enbrel accounted for 57% of the projected negative financial impact despite representing only 11% of the drug volume a...

Approximately 70% of patients served by UMass Memorial Medical Center are covered by Medicaid, Medicare, or are self-pay.